Zamira Vanessa Diaz Riascos I am a researcher in the Drug Delivery and Targeting (DDT) group, and our research is focused on improving the treatment of minority diseases such and cancer using nanomedicine in animal models. In addition, I am responsible for the in vivo section of the Functional Validation & Preclinical Research (FVPR) platform of the Nanbiosis U20. Instituciones de las que forman parte Investigador/a principal Bioquímica Clínica, Vehiculización de Fármacos y Terapia Vall Hebron Institut de Recerca Email Zamira Vanessa Diaz Riascos Email Instituciones de las que forman parte Investigador/a principal Bioquímica Clínica, Vehiculización de Fármacos y Terapia Vall Hebron Institut de Recerca I am a researcher in the Drug Delivery and Targeting (DDT) group, and our research is focused on improving the treatment of minority diseases such and cancer using nanomedicine in animal models. In addition, I am responsible for the in vivo section of the Functional Validation & Preclinical Research (FVPR) platform of the Nanbiosis U20.
I obtained the degree of Biology from the Autonomous University of Barcelona (Spain) in 2007. Also, in the same year I obtained the title of Official Master's Degree in Advanced Genetics from the Autonomous University of Barcelona. During my PhD in the laboratory of Dr. Gabriel Capellà (ICO-IDIBELL, Barcelona, Spain), I implanted an orthotopic mouse model, perpetuating human pancreatic ductal adenocarcinoma (PDAC) tissues. I gained a strong understanding of mouse surgery with considerable experience including: handling of clinical human samples, processing of samples derived from mouse models, and data analysis. My project focused on a molecular biology study characterizing the most frequent genes involved in this type of tumor. In addition, during my PhD I investigated the role of microRNAs, the miR-200 family, and ZEBs in PDAC primary tumors, patient-derived xenografts, and in cells that overexpress miR-200 by lentivirus transduction. I did an 11-month stay at the “Centre de recherches en cancerologie” of Toulouse, Inserm-Université Toulouse, France, under the supervision of Dr. Pierre Cordelier. Where I was trained to produce lentivirus, development of experiments with cell cultures and Western Blot analysis. Since 2016, I have been in the area of Functional Validation & Preclinical Research (FVPR) and I am currently responsible for the in vivo section, I also have a postdoctoral position in the Drug Delivery and Targeting group led by Dr. Abasolo. I have participated in multiple projects international and national studies using animal models for the validation of new therapeutic targets and new components of nanomedicine for cancer therapy. I recently participated in the development of the preclinical part of the Nocanther project, where magnetic hyperthermia in combination with chemotherapy was studied in a mouse model for the treatment of advanced pancreatic cancer. Nocanther is currently in the clinical phase. In addition, in these last 5 years, I have gained great experience in the field of lysosomal diseases, such as Fabry disease. In this case, I have studied the liposomes and extracellular vesicles as transport agents for the enzyme absent in this disease (GLA). I have carried out studies on the toxicity, biodistribution and efficacy of these nanoparticles in a GLA-deficient mouse model, obtaining published results. I am currently managing and maintaining a colony of transgenic mice. I also participate in a European project (Mimickey) that studies the disease of pycnodysosotosis (cathesin deficiency). In addition, I have extensive experience in experimental imaging models and functional applications of bioluminescent or fluorescent non-invasive optical imaging. Work under ISO9001 conditions.
Líneas de investigación Desenvolupament de models animals per l'avaluació ràpida i eficient de tractaments nanotecnològics IP: Zamira Vanessa Diaz Riascos Proyectos TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas IP: Begoña Benito Villabriga Colaboradores: Carmen Escudero Iriarte, Laia Ventura i Expósito, Susana Otero Romero, Ibane Abasolo Olaortua, Ignacio Ferreira González, José Antonio Barrabés Riu, Carlos Nos Llopis, Pablo Velasco Puyó, Jose Fernando Rodríguez Palomares, María Rosario Pérez- Torres Lobato, Sunny Malhotra Sareen, Belen Perez Dueñas, Jaume Sastre Garriga, Joan López Hellin, Antonia Sambola Ayala, Jordi Rio Izquierdo, Nuria Rivas Gandara, Jordi Perez Rodon, Aroa Soriano Fernández, Manuel Comabella Lopez, Antonio Rodríguez Sinovas, Gisela Teixido Tura, Antonia Pijuan Domenech, Roser Ferrer Costa, Joaquin Seras Franzoso, Carmen Tur Gomez, Maria Cristina Díaz de Heredia Rubio, Laia Yañez Bisbe, Julia German Cortes, Maria Jose Pérez García, Miguel Segura Ginard, Diego Baranda Martínez-Abasca, Cristina Auger Acosta, Neus Bellera Gotarda, Herena Eixarch Ahufinger, M Mar Mañu Pereira, Deborah Pareto Onghena, Lorena Valero Arrese, Aitor Uribarri Gonzalez, Jordi Bañeras Rius, Alex Rovira Cañellas, Mar Tintore Subirana, Bruno García del Blanco, Maria Teresa Salcedo Allende, Marisol Ruiz Meana, Ana Belén Méndez Fernández, Xavier Montalban Gairín, Simon Schwartz Navarro, Anna Llort Sales, Carmen Espejo Ruiz, Raquel Hladun Alvaro, Angels Alcina Mila, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Ana Zabalza de Torres, Marc Miquel Moltó Abad, Javier Inserte Igual, Luciana Midaglia Fernandez, Elizabeth Pando Rau, Gabriela Guillén Burrieza, Ana Laura Cazurro Gutierrez, David Gómez Andrés, Alvaro Cobo Calvo, Alvaro Calabuig Goena, Joaquin Castillo Justribo, Lydia Dux-Santoy Hurtado, Lucas Moreno Martín-Retortillo, Andres Miguez Gonzalez, Josep Roma Castanyer, Laura Dos Subirá, Nicolás Miguel Fissolo, Maria Nazarena Pizzi, Tian Tian, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Andrea Guala Entidad financiadora: Instituto de Salud Carlos III Financiación: 2494527.53 Referencia: FORT23/00034 Duración: 01/01/2024 - 31/12/2027 Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT) IP: Ibane Abasolo Olaortua Colaboradores: José Antonio Arranz Amo, Raquel Barquin Del Pino, Laura Conesa Milian, Clara Ramírez Serra, Yolanda Villena Ortiz, Joan López Hellin, Albert Blanco Grau, Roser Ferrer Costa, Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Laura Castillo Ribelles, Clara Carnicer Cáceres, Marina Giralt Arnaiz, Ana Gomez Garcia, Simon Schwartz Navarro, Pablo Gabriel Medina, Zamira Vanessa Diaz Riascos, Marc Miquel Moltó Abad, Laura Castellote Bellés, Daniel Bravo Nieto, Luz María Cruz Carlos, Clara Sanz Gea, Alba Estela García Fernández, Maria del Pilar Reimundo Diaz-Fierros, Belen Garcia Prats, Noelia Díaz Troyano, JAUME VIMA BOFARULL, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Maria Francesca Cortese, Sandra Mancilla Zamora Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca Financiación: 60000 Referencia: 2021 SGR 01173 Duración: 01/01/2022 - 30/06/2025 Impacto y valor pronóstico de vesículas extracelulares tumorales provenientes de células madre cancerígenas en tumores de mama triple negativo. IP: Joaquin Seras Franzoso Colaboradores: Laura García Latorre, Diego Baranda Martínez-Abasca, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Belen Garcia Prats Entidad financiadora: Instituto de Salud Carlos III Financiación: 99220 Referencia: PI22/01301 Duración: 01/01/2023 - 31/12/2025 Vesículas extracelulares para el tratamiento de enfermeades lisosomales (Título provisional) IP: Ibane Abasolo Olaortua Colaboradores: Laura García Latorre, Guillem Pintos Morell, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Marc Miquel Moltó Abad, Zamira Vanessa Diaz Riascos, Zamira Vanessa Diaz Riascos Entidad financiadora: Instituto de Salud Carlos III Financiación: 153670 Referencia: PI21/00936 Duración: 01/01/2022 - 30/06/2025 Paginación Página actual 1 Página 2 Página 3 Siguiente página › Última página »
